All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Hun Lee, MD Anderson Cancer Centre, Texas, US. We asked about the benefits of targeting ROR-1 with zilovertamab in patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
Targeting ROR-1 with zilovertamab in MCL and CLL
Lee provides a summary of the latest safety and efficacy data from a phase I/II study of zilovertamab + ibrutinib in relapsed/refractory CLL and MCL, outlining the encouraging progression-free survival rates seen even in high-risk patients with TP53 alterations. Lee then discusses plans for further study of the apparent synergy between zilovertamab and ibrutinib and a phase III study of zilovertamab + ibrutinib versus ibrutinib + placebo in R/R MCL to validate these findings
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
ICML 2019 | Practice-changing abstracts
Practice-changing abstracts presented during the ICML 2019 conference.
Dr Francesc Bosch | ASH 2017 | Do you believe checkpoint inhibitors will become the standard of care in CLL?
59th ASH Annual Meeting and Exposition, 9 - 12 Dec 2017, Atlanta, GA Dr Francesc Bosch Interview topic: Do you believe that checkpoint...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox